Global Startups Insights
Lets your startup
Funding News, USA Startup Funding News, Wisconsin

Retham Technologies Raises $1.5M in Seed Round

September 15, 2026
By
Loren Baker
Retham Technologies Raises $1.5M in Seed Round

Retham Technologies, a Wauwatosa, Wisconsin-based clinical diagnostics company, has raised $1.5 million in seed funding.

The round was led by Talents Fund, with participation from Golden Angels Investors and Milwaukee Venture Partners.

Retham Technologies is developing HITDx, a diagnostic test for heparin-induced thrombocytopenia (HIT), a potentially life-threatening reaction to the blood thinner heparin that can cause dangerous blood clots.

HITDx is designed to provide faster functional testing for HIT in hospital and clinical laboratories. The test uses Retham’s proprietary Cryoplatelet technology, which uses long-term-stable, cryopreserved donor platelets instead of fresh donor platelets.

“HIT demands a reliable answer quickly, but access to fresh donor platelets limits functional testing,” said Curtis Jones. “Retham’s technology will decentralize functional HIT testing by incorporating long-term-stable, responsive platelets. Additional potential applications of this technology include platelet immunology, blood research, clinical diagnostics and drug de-risking.”

The technology could help hospitals avoid delays associated with traditional functional HIT testing, which often requires fresh donor platelets and specialized laboratories.

Retham plans to use the new funding to advance HITDx through clinical validation, FDA 510(k) clearance activities and commercial preparation.

Led by CEO Steven Visuri, Retham Technologies was founded around platelet testing and research technology developed by Dr. Anand Padmanabhan and Curtis Jones. The company has also received $4.8 million in non-dilutive funding from the National Institutes of Health.

“This financing and the NIH SBIR awards validate both the clinical need and Retham’s commercial opportunity,” said Steven Visuri, Ph.D., CEO of Retham Technologies. “We are now well positioned to advance HITDx through clinical validation, FDA 510(k) clearance activities, manufacturing scale up, and commercial readiness with our goal to make highly accurate functional HIT testing practical for routine clinical laboratories and enable faster more informed treatment decisions.”

“Retham combines an urgent clinical need, differentiated proprietary platelet technology and exceptional scientific leadership,” said Dan Sem, general partner at Talents Fund. “We are proud to support the team as it moves HITDx toward the clinical market.”

Retham’s platelet technology could also support other diagnostic testing, blood research and drug development applications beyond its lead HIT diagnostic.

Recommended Stories for You